- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S5821
|
In vitro |
DMSO
: 56 mg/mL
(199.67 mM)
Ethanol : 56 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 280.45 | Formula | C18H32O2 |
Storage (From the date of receipt) | 2 years -20°C(in the dark) liquid |
|---|---|---|---|---|---|
| CAS No. | 60-33-3 | -- | Storage of Stock Solutions |
|
|
| Synonyms | 9,12-octadecadienoic acid | Smiles | CCCCCC=CCC=CCCCCCCCC(=O)O | ||
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06274788 | Not yet recruiting | Parenteral Nutrition Associated Liver Disease (PNALD)|Essential Fatty Acid Deficiency|Malnutrition|Pediatric ALL |
Fresenius Kabi |
May 1 2024 | Phase 4 |
| NCT05556967 | Completed | Adherence Patient |
University of Mississippi Medical Center|University of Mississippi National Center for Natural Products Research|National Center for Complementary and Integrative Health (NCCIH) |
August 9 2023 | Not Applicable |
| NCT05788588 | Active not recruiting | Parenteral Nutrition |
Fujian Shengdi Pharmaceutical Co. Ltd. |
April 28 2023 | Phase 3 |
| NCT05242224 | Recruiting | Growth Disorders|Malnutrition Fetal|Stunting|Development; Delayed Malnutrition|Nutrition Disorder Fetal|Maternal Nutritional Disorders Affecting Fetus or Newborn |
Washington University School of Medicine|St. Louis Children''s Hospital|St. Louis University|Children''s Discovery Institute|Universidad San Francisco de Quito |
January 5 2022 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.